Colrain Capital’s Bristol-Myers Squibb BMY Stock Holding History

Colrain Capital’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12M	Buy	208,145 +5,700	+3%	+$327K	4.06%	12
2026 Q1	$12.3M	Buy	202,445 +50,745	+33%	+$2.96M	4.75%	10
2025 Q4	$8.18M	Sell	151,700 -26,325	-15%	-$1.27M	4.5%	10
2025 Q3	$8.03M	Buy	178,025 +54,025	+44%	+$2.52M	4.57%	9
2025 Q2	$5.74M	Sell	124,000 -9,000	-7%	-$442K	4.43%	9
2025 Q1	$8.11M	Buy	133,000 +11,500	+9%	+$670K	6.93%	5
2024 Q4	$6.87M	Buy	+121,500	New	+$6.79M	6.74%	5
2014 Q1	–	Sell	-1,000	Closed	-$53K	–	109
2013 Q4	$53K	Sell	1,000 -1,500	-60%	-$76.4K	﹤0.01%	105
2013 Q3	$116K	Sell	2,500 -1,000	-29%	-$43.9K	0.01%	99
2013 Q2	$156K	Buy	+3,500	New	+$152K	0.01%	95

Other funds holding BMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Colrain Capital's BMY Position: Q2 2026 in Review

Colrain Capital increased its Bristol-Myers Squibb (BMY) stake by 2.8% in Q2 2026, buying an estimated $327K and bringing the position to 208,145 shares worth $12M. The position accounts for 4.06% of the portfolio, ranked #12.

Colrain Capital first reported a position in BMY in Q2 2013 and has held it in 10 quarters since. The position peaked at $12.3M in Q1 2026. 2,517 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

Colrain Capital held 208,145 shares of Bristol-Myers Squibb worth $12M as of Q2 2026.
Colrain Capital bought 5,700 Bristol-Myers Squibb shares in Q2 2026, an estimated $327K.
Bristol-Myers Squibb made up 4.06% of Colrain Capital's portfolio in Q2 2026, its #12 holding.
Colrain Capital first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 10 quarters since.
Colrain Capital's Bristol-Myers Squibb position peaked at $12.3M in Q1 2026.
2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Colrain Capital's 13F filing for Q2 2026, filed 5 Aug 2026.